See more : MHP SE (MHPSY) Income Statement Analysis – Financial Results
Complete financial analysis of 180 Life Sciences Corp. (ATNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of 180 Life Sciences Corp., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Jaws Juggernaut Acquisition Corporation (JUGGW) Income Statement Analysis – Financial Results
- Goldstone Capital Group Limited (1160.HK) Income Statement Analysis – Financial Results
- EarthRenew Inc. (ERTH.CN) Income Statement Analysis – Financial Results
- Silver Range Resources Ltd. (SLRRF) Income Statement Analysis – Financial Results
- PT Bank Nationalnobu Tbk (NOBU.JK) Income Statement Analysis – Financial Results
180 Life Sciences Corp. (ATNF)
About 180 Life Sciences Corp.
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 0.00 | 0.00 |
| Gross Profit | -105.68K | -109.00K | -116.30K | -125.33K | -72.24K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.78M | 2.43M | 3.95M | 2.29M | 2.04M | 1.07M | 0.00 |
| General & Administrative | 10.69M | 15.47M | 11.69M | 3.32M | 5.89M | 7.67M | 343.88K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 38.83K | 12.96M | 0.00 | 0.00 |
| SG&A | 10.69M | 15.47M | 11.69M | 3.36M | 18.85M | 7.67M | 343.88K |
| Other Expenses | 0.00 | 246.34B | 770.60K | 264.74K | 250.40K | 0.00 | 0.00 |
| Operating Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Cost & Expenses | 13.48M | 39.64M | 20.16M | 9.82M | 25.22M | 14.51M | 343.88K |
| Interest Income | 0.00 | 26.67K | 186.21K | 1.09M | 181.41K | 12.24K | 663.02K |
| Interest Expense | 44.83 | 26.67K | 186.21K | 1.09M | 185.14K | 0.00 | 0.00 |
| Depreciation & Amortization | 105.68K | 109.00K | 116.30K | 125.33K | 72.24K | 23.08K | 52.52K |
| EBITDA | -22.13M | -17.79M | -20.05M | -5.52M | -20.79M | -8.72M | -343.88K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.48M | -17.90M | -15.64M | -5.65M | -20.86M | -8.74M | -343.88K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.81M | -21.77M | -4.71M | -5.26M | -4.54M | -5.75M | 663.02K |
| Income Before Tax | -22.28M | -39.67M | -20.35M | -10.90M | -25.40M | -14.50M | 319.13K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.35M | 942.75K | 23.20K | 20.43K | 9.50K | -1.00 | 195.37K |
| Net Income | -19.94M | -38.73M | -20.32M | -12.01M | -25.39M | -14.50M | 123.76K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -52.60 | -387.26 | -247.86 | -255.46 | -875.66 | -1.45K | 12.38 |
| EPS Diluted | -52.59 | -387.18 | -246.32 | -251.32 | -874.45 | -1.45K | 12.38 |
| Weighted Avg Shares Out | 379.00K | 100.00K | 82.00K | 47.00K | 29.00K | 10.00K | 10.00K |
| Weighted Avg Shares Out (Dil) | 379.09K | 100.02K | 82.51K | 47.77K | 29.04K | 10.00K | 10.00K |
Why 180 Life Sciences Stock Is Falling Today
Another capital raise less than a year after the company's stock market debut is more than a little troubling.
180 Life Sciences Corp. Announces $15.0 Million Private Placement
PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue
Collaboration Between the Pioneer of Cannabis Chemistry in Israel, Professor Raphi Mechoulam, Sir Marc Feldmann's Laboratory in Oxford, and 180 Life Sciences Scientists, Identifies a Non-Psychoactive Cannabidiol (CBD) Analogue Expected to Move Forward in Clinical Development for Inflammation and Pain...
180 Life Science Corp Nears Key Levels And Could Breakout Soon
180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher Monday after the company announced it regained compliance with the Nasdaq. The company was notified Jan. 6 it did not meet the listing requirements for the Nasdaq.
180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)
MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
180 Life Sciences Joins Russell Microcap® Index
MENLO PARK, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors
MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors
MENLO PARK, Calif., May 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q
MENLO PARK, Calif., May 21, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K
MENLO PARK, Calif., April 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis...
Source: https://incomestatements.info
Category: Stock Reports